ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Methotrexate

Also written as “methotrexate”, “Methotrexate (MTX)” and “MTX”.

Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Gout · Arthritis, Psoriatic · Arthritis, Juvenile, led by 24 companies.

Drug pageMethotrexate: every studyMany companies study it; this page follows only the 93 they lead. All 627 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 18, 200793 company-led studies, 4 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only360 open or runningphase 4since Apr 18, 2007Oct 21, 2005none ahead
Bristol-Myers Squibbits history only91 open or runningphase 4since Sep 4, 2015Jul 19, 2005none ahead
Pfizerits history only80 open or runningphase 4since Sep 8, 2005Sep 8, 2005none ahead
AbbVieits history only60 open or runningphase 4since May 25, 2010Sep 13, 2005none ahead
Johnson & Johnsonits history only60 open or runningphase 3since Dec 11, 2005Dec 11, 2005none ahead
Aldeyra Therapeuticsits history only31 open or runningphase 3since Oct 21, 2019Oct 21, 2019Dec 2029phase 3 · NCT07402876
AstraZenecaits history only30 open or runningphase 4since Aug 23, 2023Sep 16, 2005none ahead
medac31 open or runningphase 3since Jan 11, 2024May 14, 2013Nov 2026phase 3 · NCT06239311
Merckits history only30 open or runningphase 3since Aug 18, 2006Aug 18, 2006none ahead
Halozyme Therapeuticsits history only20 open or runningphase 2since Jun 4, 2012Jun 4, 2012none ahead

Also a collaborator on its studies: Lakefront Biotherapeutics NV, Roche Pharma, Regeneron Pharmaceuticals, Integrated Therapeutics Group, Accutest Research Laboratories (I) Pvt., PPD DEVELOPMENT, LP, UCB, Immunex, Basilea Pharmaceutica International, Tanabe Pharma, Astellas Pharma US and Eisai.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of medac only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 14, 2013First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT01871961 · 105 enrolled · United States
  2. Mar 24, 2014Phase 1 study in PsoriasisNCT02097173 · 35 enrolled · United States
  3. Jan 11, 2024Phase 3 study in Moderate to Severe Atopic DermatitisNCT06239311 · 277 planned · Czechia, France, Italy and more

Ahead

  1. Nov 2026Primary completion: phase 3 study in Moderate to Severe Atopic DermatitisNCT06239311

TargetBeta

DHFR →read by rule
“Dihydrofolate reductase inhibitor; Dihydrofolate reductase inhibitor”ChEMBL 37, by rule

Other programs on DHFR

ProgramCompanyFurthest phaseStudies
PemetrexedruleEli Lillyphase 4141
pralatrexateruleAurobindo Pharmaphase 419

Studies

All 3 medac leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06239311Moderate to Severe Atopic Dermatitis · Czechia, France, Italy and more3RecruitingNov 2026277
NCT02097173Psoriasis · United States1CompletedOct 201335
NCT01871961Arthritis, Rheumatoid · United States1CompletedFeb 2013105

How it is read

Names in the registry

  • “Methotrexate”, 71 entries
  • “methotrexate”, 28 entries
  • “Methotrexate (MTX)”, 7 entries
  • “MTX”, 4 entries
  • “methotrexate (MTX)”, 3 entries

Codes read as this program: ADX2191.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.